BACKGROUND: E (epithelial)-cadherin, the cell adhesion molecule also considered a potential invasion/metastasis suppressor, is mutationally inactivated in nearly half of all undifferentiated-scattered (diffuse-type) gastric carcinomas. In addition, silencing of E-cadherin by CpG methylation within its promoter region has been reported in several gastric carcinoma cell lines. We investigated the methylation status of the E-cadherin promoter region in 53 primary human gastric carcinomas. METHODS: Hypermethylation of the E-cadherin promoter was determined by utilizing methylation-specific polymerase chain reaction (PCR)-single-strand conformation polymorphism (MSP-SSCP) analysis followed by direct sequencing of PCR products. Expression of E-cadherin was studied by western blot analysis. All statistical tests were two-sided. RESULTS: Hypermethylation of the E-cadherin promoter was evident in 27 (51%) of 53 primary gastric carcinomas examined by MSP-SSCP. It occurred more frequently in carcinomas of the undifferentiated-scattered type (in 15 [83%] of 18) than in other histologic subtypes (in 12 [34%] of 35) (P =.0011, Fisher's exact test), and it was present at similar rates in early (in six [60%] of 10) versus advanced (in 21 [49%] of 43) carcinomas (P =.73, Fisher's exact test). Methylation occurring at all cytosine-guanosine sequences (CpGs) near the transcriptional start site was confirmed in six of six tumors examined by bisulfite-DNA sequencing, including two early gastric carcinomas. In addition, loss or diminished expression of E-cadherin was confirmed by western blotting in four of the six tumor tissues demonstrating hypermethylation. CONCLUSIONS: The E-cadherin promoter frequently undergoes hypermethylation in human gastric cancers, particularly those of the undifferentiated-scattered histologic subtype. E-cadherin promoter hypermethylation is associated with decreased expression and may occur early in gastric carcinogenesis.
BACKGROUND: E (epithelial)-cadherin, the cell adhesion molecule also considered a potential invasion/metastasis suppressor, is mutationally inactivated in nearly half of all undifferentiated-scattered (diffuse-type) gastric carcinomas. In addition, silencing of E-cadherin by CpG methylation within its promoter region has been reported in several gastric carcinoma cell lines. We investigated the methylation status of the E-cadherin promoter region in 53 primary humangastric carcinomas. METHODS: Hypermethylation of the E-cadherin promoter was determined by utilizing methylation-specific polymerase chain reaction (PCR)-single-strand conformation polymorphism (MSP-SSCP) analysis followed by direct sequencing of PCR products. Expression of E-cadherin was studied by western blot analysis. All statistical tests were two-sided. RESULTS: Hypermethylation of the E-cadherin promoter was evident in 27 (51%) of 53 primary gastric carcinomas examined by MSP-SSCP. It occurred more frequently in carcinomas of the undifferentiated-scattered type (in 15 [83%] of 18) than in other histologic subtypes (in 12 [34%] of 35) (P =.0011, Fisher's exact test), and it was present at similar rates in early (in six [60%] of 10) versus advanced (in 21 [49%] of 43) carcinomas (P =.73, Fisher's exact test). Methylation occurring at all cytosine-guanosine sequences (CpGs) near the transcriptional start site was confirmed in six of six tumors examined by bisulfite-DNA sequencing, including two early gastric carcinomas. In addition, loss or diminished expression of E-cadherin was confirmed by western blotting in four of the six tumor tissues demonstrating hypermethylation. CONCLUSIONS: The E-cadherin promoter frequently undergoes hypermethylation in humangastric cancers, particularly those of the undifferentiated-scattered histologic subtype. E-cadherin promoter hypermethylation is associated with decreased expression and may occur early in gastric carcinogenesis.
Authors: Wen Quan Jonathan Goh; Ghim Siong Ow; Vladimir A Kuznetsov; Shirly Chong; Yoon Pin Lim Journal: Am J Transl Res Date: 2015-06-15 Impact factor: 4.060
Authors: Kiyomi O Toyooka; Shinichi Toyooka; Anirban Maitra; Qinghua Feng; Nancy C Kiviat; Alice Smith; John D Minna; Raheela Ashfaq; Adi F Gazdar Journal: Am J Pathol Date: 2002-08 Impact factor: 4.307
Authors: Elena Prieto-García; C Vanesa Díaz-García; Inmaculada García-Ruiz; M Teresa Agulló-Ortuño Journal: Med Oncol Date: 2017-05-30 Impact factor: 3.064
Authors: Anke H van der Ploeg; Oliver Kumpf; Evelyn Seelow; Luis C Berrocal Almanza; Peter M Schlag; Ralf R Schumann; Lutz Hamann Journal: Gastric Cancer Date: 2014-02-21 Impact factor: 7.370
Authors: Rohit R Sharma; Mark J London; Laura L Magenta; Mitchell C Posner; Kevin K Roggin Journal: J Gastrointest Surg Date: 2009-06-10 Impact factor: 3.452
Authors: Rachana Agarwal; Yuriko Mori; Yulan Cheng; Zhe Jin; Alexandru V Olaru; James P Hamilton; Stefan David; Florin M Selaru; Jian Yang; John M Abraham; Elizabeth Montgomery; Patrice J Morin; Stephen J Meltzer Journal: PLoS One Date: 2009-11-24 Impact factor: 3.240